Top 5 Target	Count

PIP4K2C(phosphatidylinositol-5-phosphate 4-kinase type 2 gamma)	20
PDCD2(programmed cell death 2)	9
SARS-CoV-2 S protein	5
EGFR(Epidermal growth factor receptor erbB1)	5
MKK7(mitogen-activated protein kinase kinase 7)	4

164

Drugs associated with Stanford University

Ipilimumab

Target

CTLA4

Mechanism

CTLA4 inhibitors

Active Org.

National Cancer Institute [+17]

Originator Org.

Bristol Myers Squibb Co.

Active Indication

PD-L1 positive Non-Small Cell Lung Cancer [+290]

Inactive Indication

Acute lymphoblastic leukemia recurrent [+130]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date25 Mar 2011

Naltrexone

Target

Opioid receptors x μ opioid receptor

Mechanism

Opioid receptors antagonists [+1]

Active Org.

The Children's Mercy Hospital [+13]

Originator Org.

Alkermes, Inc.

Active Indication

Opium Dependence [+13]

Inactive Indication

Acquired Immunodeficiency Syndrome [+34]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date13 Apr 2006

Hymecromone

Target

Hyaluronic acid

Mechanism

Hyaluronic acid modulators

Active Org.

Stanford University [+1]

Originator Org.-

Active Indication

Cholestasis [+4]

Inactive Indication

Multiple Sclerosis

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date-

2,828

Clinical Trials associated with Stanford University

NCT05945147

/ WithdrawnPhase 2IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

Start Date01 Jan 2099

Sponsor / Collaborator

Stanford University

NCT04027569

/ WithdrawnNot ApplicableIIT

PROMs To Improve Care: A Pragmatic RCT on Standardized and Patient Specific PROMs on Outcomes After Hand Surgery

To examine the impact of using 2 validated PROMs during the care of an orthopaedic condition on shared decision making, patient centered care, and patient outcomes.

Start Date01 Nov 2040

Sponsor / Collaborator

Stanford University

NCT04291170

/ WithdrawnNot ApplicableIIT

Comparison of Upper Extremity and Lower Extremity Function and Quick DAS

Patient reported outcome measure (PROM) are a method by which to assess outcomes from a patient perspective. The QuickDASH is a commonly used PROM. QDASH was validated against grip strength and ability work, however not against its ability to actually measure what it sets forth to measure (ie: patient's ability to use a hammer, carry a shopping bag, wash a wall, etc). The purpose of this study is to correlate the self-reported QDASH with patients' ability to perform the functions on the QDASH and compare to a control group who completes the task on a lower extremity PROM, KOOS JR.

Start Date01 Sep 2040

Sponsor / Collaborator

Stanford University

100 Clinical Results associated with Stanford University

0 Patents (Medical) associated with Stanford University

211,845

Literatures (Medical) associated with Stanford University

01 Jan 2026·APPETITE

Meaningfully reducing consumption of meat and animal products is an unsolved problem: A meta-analysis

Article

Author: Green, Seth Ariel ; Mathur, Maya B ; Smith, Benny

Which interventions produce the largest and most enduring reductions in consumption of meat and animal products (MAP)? We address this question with a theoretical review and meta-analysis of randomized controlled trials that measured MAP consumption at least one day after intervention. We meta-analyze 35 papers comprising 41 studies, 112 interventions, and approximately 87,000 subjects. We find that these papers employ four major strategies to change behavior: choice architecture, persuasion, psychology (manipulating the interpersonal, cognitive, or affective factors associated with eating MAP), and a combination of persuasion and psychology. The pooled effect of all 112 interventions on MAP consumption is quite small (standardized mean difference (SMD) = 0.07 (95 % CI: [0.02, 0.12]), indicating an unsolved problem. Interventions aiming to reduce only consumption of red and processed meat were more effective (SMD = 0.25; 95 % CI: [0.11, 0.38]), but it remains unclear whether such interventions also decrease consumption of other forms of MAP. We conclude that while existing approaches do not provide a proven remedy to MAP consumption, designs and measurement strategies have generally been improving over time, and many promising interventions await rigorous evaluation.

01 Jan 2026·Neural Regeneration Research

Enhanced neurogenesis after ischemic stroke: The interplay between endogenous and exogenous stem cells

Article

Author: Wang, Yuhe ; Wu, Jun ; Geng, Ruxu ; Wang, Renzhi ; Bao, Xinjie

Ischemic stroke is a significant global health crisis, frequently resulting in disability or death, with limited therapeutic interventions available. Although various intrinsic reparative processes are initiated within the ischemic brain, these mechanisms are often insufficient to restore neuronal functionality. This has led to intensive investigation into the use of exogenous stem cells as a potential therapeutic option. This comprehensive review outlines the ontogeny and mechanisms of activation of endogenous neural stem cells within the adult brain following ischemic events, with focus on the impact of stem cell-based therapies on neural stem cells. Exogenous stem cells have been shown to enhance the proliferation of endogenous neural stem cells via direct cell-to-cell contact and through the secretion of growth factors and exosomes. Additionally, implanted stem cells may recruit host stem cells from their niches to the infarct area by establishing so-called “biobridges.” Furthermore, xenogeneic and allogeneic stem cells can modify the microenvironment of the infarcted brain tissue through immunomodulatory and angiogenic effects, thereby supporting endogenous neuroregeneration. Given the convergence of regulatory pathways between exogenous and endogenous stem cells and the necessity for a supportive microenvironment, we discuss three strategies to simultaneously enhance the therapeutic efficacy of both cell types. These approaches include: (1) co-administration of various growth factors and pharmacological agents alongside stem cell transplantation to reduce stem cell apoptosis; (2) synergistic administration of stem cells and their exosomes to amplify paracrine effects; and (3) integration of stem cells within hydrogels, which provide a protective scaffold for the implanted cells while facilitating the regeneration of neural tissue and the reconstitution of neural circuits. This comprehensive review highlights the interactions and shared regulatory mechanisms between endogenous neural stem cells and exogenously implanted stem cells and may offer new insights for improving the efficacy of stem cell-based therapies in the treatment of ischemic stroke.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study

Article

Author: Mejia, Jaime A. ; Kurian, Allison W. ; Mahendran, Malena ; Song, Yan ; Hirshfield, Kim M. ; Sun, Yezhou ; Earla, Jagadeswara Rao ; Hua, Qi ; Kponee-Shovein, Kalé ; Hilts, Annalise

AIM:

This study aimed to describe treatment patterns and quantify the economic impact of recurrence in early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC).

MATERIALS & METHODS:

Medicare beneficiaries with stages I-III HER2-negative BC and lumpectomy or partial/total mastectomy were identified from SEER-Medicare data (2010-2019). Perioperative therapies were reported in the neoadjuvant and adjuvant setting. Locoregional recurrence and distant metastasis were identified using a claims-based algorithm developed with clinical input and consisting of a diagnosis-based and treatment-based indicator. All-cause and BC-related healthcare resource utilization (HRU) per-patient-month and monthly healthcare costs were estimated from the recurrence date for patients with recurrence and from an imputed index date for patients without recurrence using frequency matching. HRU and costs were compared between groups stratified by hormone receptor-positive (HR+) or triple negative BC (TNBC) using multivariable regression models.

RESULTS:

Of 28,655 patients, 8.5% experienced recurrence, 90.4% had HR+ disease, and 5.6% received neoadjuvant therapy. Relative to patients without recurrence, patients with recurrence had more advanced disease (stage II/III: 73.7% vs. 34.0%) and higher-grade tumors (Grade 3/4: 40.6% vs. 18.0%) at diagnosis. Recurrence in HR+/HER2-negative BC and TNBC was associated with higher rates of all-cause hospitalizations (incidence rate ratio [IRR]: 2.84 and 3.65), emergency department (ED) visits (IRR: 1.75 and 2.00), and outpatient visits (IRR: 1.46 and 1.55; all p < 0.001). Similarly, recurrence was associated with higher rates of BC-related HRU, particularly for ED visits in HR+/HER2-negative BC (IRR: 4.24; p < 0.001) and hospitalizations in TNBC (IRR: 11.71; p < 0.001). Patients with HR+/HER2-negative BC and TNBC recurrence incurred higher monthly all-cause (cost difference [CD]: $3988 and $4651) and BC-related healthcare costs (CD: $3743 and $5819).

CONCLUSIONS:

Our findings highlight the considerable economic burden of recurrence in early-stage HER2-negative BC and underscore the unmet need for optimization of therapies that reduce recurrence in this population.

2,449

News (Medical) associated with Stanford University

12 Aug 2025

·www.prnewswire.com

VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

WENZHOU, China, Aug. 12, 2025 /PRNewswire/ -- Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine; he is also a professor of medicine (immunology and rheumatology) and professor of pediatrics at Stanford. Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular AMD, and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous clinical trials involving novel therapeutic agents. Professor Nguyen was among the first clinician scientists in the world to evaluate the safety and efficacy of aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME), which became the foundation for subsequent trials leading to FDA approval of anti-VEGF therapy for retinal vascular diseases. He also led other trials, including READ-2, READ-3, and iDEAL studies for diabetic macular edema and SAVE, SAVE-2, STOP-UVEITIS, SATURN, ACTHAR, and ATLAS, and recently LEOPARD and LION studies for uveitis and ocular inflammatory diseases. Dr. Nguyen received both B.S. and M.Sc. in Molecular Biophysics and Biochemistry from Yale and M.D. from the University of Pennsylvania Perelman School of Medicine. He completed his internship in Internal Medicine at the Massachusetts General Hospital and residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Dr. Nguyen also obtained fellowships in Uveitis as well as Vitreoretinal Surgery at the Massachusetts Eye and Ear Infirmary, and Ocular Immunology at the Wilmer Eye Institute, Johns Hopkins University. Dr. Nguyen is a member of many prestigious organizations, including the Macula Society, the Retina Society, the American Society of Retina Specialists, the Club Jules Gonin, the American Ophthalmological Society, the Association for Research in Vision and Ophthalmology, the International Uveitis Study Group, the Foster Ocular Immunology Society, and the American Uveitis Society, among others. Professor Nguyen is the current President of the International Ocular Inflammation Society, which is the largest society in the world devoted to ocular inflammation. Dr. Wang Shen, Founder and Chief Executive Officer of VivaVision Biotech, stated: "We are very honored to welcome Professor Quan Dong Nguyen as a member of VivaVision Biotech's Scientific Advisory Board (SAB). Professor Quan Dong Nguyen's expertise and extensive experience in diabetic/uveitis-related macular edema, neovascular age-related macular degeneration (AMD), and intraocular inflammatory diseases will help VivaVision to further its innovative pipeline. In particular, we look forward to collaborating with Professor Quan Dong Nguyen on our dual JAK1/TYK2 inhibitor VVN461 (an ophthalmic solution) and VVN481 (a suspension for suprachoroidal injection). VivaVision will continue to strengthen its capabilities in R&D innovation, advance its pipeline both in China and abroad, and establish ourselves as a global leader in ophthalmic drug discovery." "It is a tremendous pleasure for me to join the Scientific Advisory Board at VivaVision," said Professor Nguyen. "I believe that VivaVision's JAK1/TYK2 inhibitor has the potential to be a novel therapeutic option for patients who are using and dependent on corticosteroids of different routes of administration for their ocular inflammatory diseases. I look forward to advising the Company on the clinical programs and trial preparation and the development of promising therapeutic candidates in the future." About VivaVision Biotech Founded in 2016, VivaVision Biotech is a clinical-stage pharmaceutical company dedicated to advance first-in-class and best-in-class therapies for ocular diseases. The company's leading pipeline assets include: VVN461: non-steroidal dual JAK1/TYK2 immunomodulator for post-operative inflammation after cataract surgery and non-infectious anterior uveitis. VVN001: an investigational treatment for dry eye disease. VVN1901: a therapy for neurotrophic keratitis VVN481: a non-steroidal dual JAK1/TYK2 inhibitor for suprachoroidal injection to treat posterior/pan-uveitis and posterior inflammatory diseases In addition to its pipeline, VivaVision is actively engaged in the discovery and development of innovative therapies for anterior and posterior ocular diseases to address unmet patient needs. For more information, please visit . SOURCE VIVAVISION BIOTECH LTD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

12 Aug 2025

·www.prnewswire.com

Pew Awards 22 Researchers Biomedical Science Grants

PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- The Pew Charitable Trusts today announced the 22 researchers joining the Pew Scholars Program in the Biomedical Sciences. These early-career scientists will receive four years of funding to uncover fundamental insights about human health and disease. Continue Reading "For 40 years, Pew has supported young, talented researchers as they take creative approaches to solving big scientific questions," said Donna Frisby-Greenwood, Pew's senior vice president for Philadelphia and scientific advancement. "This new class continues that legacy, and we look forward to seeing where their discoveries lead." The Pew Charitable Trusts announced the 22 researchers joining the Pew Scholars Program in the Biomedical Sciences. Post this The 2025 class—all early-career, junior faculty—marks the 40th group of Pew scholars to be awarded funding since the program's founding in 1985. They join a rich network of more than 1,000 Pew-funded scientists and will have opportunities to meet annually to exchange ideas and form collaborations across disciplines. "Pew-funded scientists have long contributed to biomedical research discoveries that have improved human health," said Lee Niswander, Ph.D., a 1995 Pew scholar and chair of the program's national advisory committee. "I'm confident this new class of scholars, with their innovative and creative approaches to scientific research, will continue this tradition." Scholars were chosen from 209 applicants nominated by leading academic institutions and researchers throughout the United States. This year's class includes scientists who are assessing how gut bacteria fights metabolic disease, examining the way the human brain develops and evolves over time, and leveraging cutting-edge technologies to prevent and treat disease. Five members of the 2025 class, who were selected for their commitment to investigating health challenges relating to the brain as it ages, will receive awards with support from the Kathryn W. Davis Peace by Pieces Fund. The 2025 Pew scholars in the biomedical sciences are: Ana Paula Arruda, Ph.D. University of California, Berkeley Dr. Arruda will explore how cells reprogram their metabolism by reorganizing subcellular architecture. Sarah Bowling, Ph.D. Stanford University School of Medicine Dr. Bowling will investigate how mammalian embryos maintain resilience in the face of injury or cell loss. Matthew Bramble, Ph.D. Children's Research Institute of Children's National Hospital Dr. Bramble will unravel the molecular biology of konzo, a neurological condition that causes paralysis in susceptible children in sub-Saharan Africa. Cara Brook, Ph.D. University of California, Berkeley Dr. Brook will design vaccines to immunize wild bats against viruses that can be transmitted to the human population. Nicholas Burton, Ph.D. Van Andel Institute Dr. Burton will dissect the molecular mechanisms that allow bacteria in the microbiome to cure metabolic diseases. Kizzmekia Corbett-Helaire, Ph.D. Harvard T.H. Chan School of Public Health Dr. Corbett-Helaire will uncover how coronaviruses and other emerging viruses, such as simian hemorrhagic fever viruses, interact with human cells. Fleur M. Ferguson, Ph.D. University of California San Diego Dr. Ferguson will design strategies for engineering nondegrader "molecular glues" that can hold together or functionally redirect the activity of specific protein complexes. Antonio Fernandez-Ruiz, Ph.D. Cornell University Dr. Fernandez-Ruiz will assess how rodents learn the spatial layout and dynamics of a changing environment and how they exploit this knowledge to guide flexible foraging behavior. Vignesh Kasinath, Ph.D. University of Colorado Boulder Dr. Kasinath will study how cells "silence" transposons, genetic elements whose movement within the genome can disrupt the function of genes. Fenna Krienen, Ph.D. Princeton University Dr. Krienen will explore whether sex differences shape how the brain's resident immune cells influence neural development and behavior. Yerbol Kurmangaliyev, Ph.D. Brandeis University Dr. Kurmangaliyev will uncover the genetic principles that guide the formation of complex neural circuits. Bianca Jones Marlin, Ph.D. Columbia University Dr. Marlin will examine the molecular mechanisms by which the effects of trauma can be passed from one generation to the next. Ewan K.S. McRae, Ph.D. Houston Methodist Research Institute Dr. McRae will determine approaches for designing stable, controllable therapeutic RNAs. Ryan Nett, Ph.D. Harvard University Dr. Nett will explore the chemistry that plants use to synthesize novel amino acids with interesting biological activities. Maria A. Nieves-Colón, Ph.D. University of Minnesota Twin Cities Dr. Nieves-Colón will investigate the genetic and health impacts of the influx of millions of Africans to Latin America in the colonial period. Jessica Osterhout, Ph.D. University of Utah Dr. Osterhout will decode how the brain senses infection to generate the symptoms associated with illness. Hijai Regina Shin, Ph.D. Children's Medical Center Research Institute at UT Southwestern Dr. Shin will investigate a novel family of intracellular signaling proteins that senses nutrients and coordinates metabolic responses. Nasa Sinnott-Armstrong, Ph.D. Fred Hutch Cancer Center Dr. Sinnott-Armstrong will develop an automated, AI-powered robotic system to identify novel therapeutics for Lyme disease. Steven Reilly, Ph.D. Yale School of Medicine Dr. Reilly will design programmable, synthetic cis-regulatory elements—DNA sequences that control gene expression—to facilitate the delivery and activation of therapeutic cargos to specific target tissues. Berna Sozen, Ph.D. Yale School of Medicine Dr. Sozen will examine how the maternal environment shapes an embryo's developmental trajectory. Zak Swartz, Ph.D. Marine Biological Laboratory Dr. Swartz will study how female sea stars continue to produce eggs throughout their decades-long lifespan. En Yang, Ph.D. University of North Carolina, Chapel Hill Dr. Yang will use a custom-made virtual reality rig to explore how the brain conjures remembered images and performs spatial navigation. Founded in 1948, The Pew Charitable Trusts uses data to make a difference. Pew addresses the challenges of a changing world by illuminating issues, creating common ground, and advancing ambitious projects that lead to tangible progress. Erin Davis, 202-540-6677, [email protected] SOURCE The Pew Charitable Trusts WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

11 Aug 2025

·www.prnewswire.com

The Galien Foundation Announces 2025 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2025 Prix Galien USA Award nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Disease." Winners will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025, at the American Museum of Natural History in New York City. Continue Reading (PRNewsfoto/The Galien Foundation) Michael Rosenblatt, MD, Chair of the Prix Galien USA Awards Committee, Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc. commented, "It is a privilege to recognize this year's nominations showcasing the latest innovations in health towards the continued improvement of the human condition. These breakthroughs reflect not only scientific ingenuity but also a profound commitment to addressing some of the world's most pressing medical challenges." Dr. Rosenblatt's recent appointment to the Board of Overseers of Harvard University, in addition to receiving Harvard Medical School's Distinguished Service Award, are a testament to his illustrious career in the life sciences. His longstanding dedication to advancing research, mentoring future leaders in medicine, and championing innovation through his involvement with The Galien Foundation continues to inspire excellence across the global healthcare landscape. The 2025 Prix Galien USA nominees include products from the following categories: "Best Biotechnology Product" – 16 nominees; "Best Pharmaceutical Product" – 18 nominees; and "Best Product for Rare/Orphan Diseases" – 13 nominees. To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact. Best Biotechnology Product (Nominees) Best Pharmaceutical Product (Nominees) Best Product for Rare/Orphan Diseases (Nominees) "The advancements made across the life sciences industries in the past year reflect a rapidly evolving landscape of innovation, which we are honored to celebrate at the Prix Galien USA Awards each year in New York City," said Bruno Cohen, Chairman of The Galien Foundation. "The Awards Committee looks forward to reviewing these outstanding submissions from leading teams and recognizing their contributions to their respective fields at the upcoming Awards ceremony." The Prix Galien USA Awards Committee is composed of 11 renowned leaders from the biomedical industry and academia, including three Nobel Laureates, responsible for evaluating nominees. Prix Galien Biotechnology, Pharmaceutical and Rare/Orphan Diseases Awards Committee 2025 Michael ROSENBLATT M.D., Galien Forum Co-Chair, Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc. Prix Galien Committee Chair Linda BUCK Ph.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics, University of Washington Sue DESMOND-HELLMANN M.D., M.P.H., Former Chief Executive Officer, Bill & Melinda Gates Foundation Laurie GLIMCHER M.D., President and CEO, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School Mary-Claire KING Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington Robert S. LANGER M.D., David H. Koch Institute Professor, Massachusetts Institute of Technology Sir Cato T. LAURENCIN M.D., Ph.D., K.C.S.L., Chief Executive Officer, The Cato T. Laurencin Institute at UConn; The University Professor and Van Dusen Distinguished Endowed Professor, University of Connecticut Steven J. LESTER M.D., Medical Director, Discovery Oasis; Founder and Chief Medical Officer, Mayo Clinic and ASU Alliance for Health Care Accelerator Stanley B. PRUSINER M.D., Nobel Laureate, Professor of Neurology, Director, Institute for Neurodegenerative Diseases, University of California, San Francisco Phillip A. SHARP Ph.D., Nobel Laureate, Professor of Biology and member of the Koch Institute, Chair of the advisory board of the MIT Jameel Clinic Marc TESSIER-LAVIGNE Ph.D., President Emeritus and Professor, Stanford University About The Galien Foundation The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The late Professor Elie Wiesel, 1986 Peace Nobel Laureate, is The Honorary Founding President of The Galien Foundation The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit  . Follow the Foundation on social media: Media Contact: Kara Bradley Finn Partners [email protected] 646-213-7243 SOURCE The Galien Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

100 Deals associated with Stanford University

100 Translational Medicine associated with Stanford University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

118

Preclinical

Phase 1

Phase 2

Phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rotavirus vaccine I321(Stanford University)	Rotavirus Infections More	Phase 3
[18F]F-AraG ( DCK x DGUOK )	Advanced Malignant Solid Neoplasm More	Phase 2
Ipilimumab ( CTLA4 )	Unresectable Melanoma More	Phase 2
QBS-10072S ( SLC7A5 )	Meningeal Neoplasms More	Phase 2
Hymecromone ( Hyaluronic acid )	Cholangitis, Sclerosing More	Phase 2

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis